GRE
INVESTMENT ADVISORS LIMITED
We are a SFC licensed corporation in Hong Kong which provides Investment Advisory and Asset Management services
GRE
INVESTMENT ADVISORS LIMITED
GRE投资咨询有限公司(“GRE”)是一家由香港证券及期货事务监察委员会(“SFC”)批准许可,
提供投资咨询和资产管理服务的公司。
ABOUT US
GRE
INVESTMENT ADVISORS LIMITED
GRE Investment Advisors Limited (“GRE”) is licensed by the Hong Kong Securities & Futures Commission (“SFC”) to provide investment advisory and asset management services, under type 4 (Advising on Securities) and Type 9 (Asset Management) licenses. Mr. Kevin Yip, Mr. Kester Ng, Mr. Jimmy Woo and Mr. Cary Zhou, the professional team has achieved outstanding equity investment return in the Greater China and Asia Pacific Region.
关于我们
GRE
INVESTMENT ADVISORS LIMITED
GRE投资咨询有限公司(“GRE”)是一家由香港证券及期货事务监察委员会(“SFC”)批准许可,提供投资咨询和资产管理服务的公司。GRE拥有第四类(证券咨询)及第九类(资产管理)牌照。在公司管理人叶家祺先生、吴绳祖先生、吴积民先生以及周永凯先生的带领下,专业团队在大中华区及亚太区都取得了杰出的股权投资回报。
PORTFOLIO
  • Animoca Brands
    Animoca is the leader in the emerging market of blockchain gaming and digital property rights based on NFTs (non-fungible tokens). The Company has a very successful portfolio of majority owned blockchain games and metaverses including the Sandbox, F1 Delta Time and RevvRacing. In addition, Animoca has over 100 strategic investments in relevant blockchain gaming and NFT projects.
    For more details,
  • Sirnaomics
    Sirnaomics is the first and only clinical-state RNA therapeutics biopharmaceutical company with a strong presence in both US and China through discovery and development of therapeutics for human disorders with unmet medical needs. The clinical development pipeline is focused on oncology and fibrosis indications. Sirnaomics was listed on the Hong Kong Stock Exchange on Dec 30, 2021 (HKSE stock code: 2257).
    For more details,
    please refer to https://sirnaomics.com
  • Genor Biopharma
    Genor Biopharma Company Limited (“Genor”) is a leading biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Based in Shanghai, the Company was a spin-off from Walvax Biotechnology Company in June 2018 that was led by Hillhouse Capital and Hangzhou Tigermed Consulting.  Genor has successfully developed drug candidates targeting pathways with blockbuster potentials, encompassing top three oncology targets and five out of the ten bestselling drugs globally. Genor has established a pipeline of 15 targeted drug candidates with strong commercialization potentials in China that cover both proven and novel biological pathways. Genor currently has around 400 employees across 3 locations in China (Shanghai, Yunnan Yuxi and Beijing) as well as a lab in San Francisco, USA.
    For more details,
  • Ping An Good Doctor (PAGD)
    PAGD was founded by the Ping An Group in August 2014. The Company is a pioneer in the PRC Internet healthcare market and operate the largest Internet healthcare platform in terms of average MAUs and daily average online consultations. Through its mobile platform launched in April 2015, PAGD offers online medical and wellness services, such as family doctor services, consumer healthcare services, health mall as well as health management and wellness interaction. PAGD was listed in the Hong Kong Stock Exchange on May 4, 2018 (HKSE stock code: 1833).
    For more details,
    please refer to https://www.jk.cn/aboutUs
  • LUFAX
    Founded by the Ping An Group in Sep 2011, Lufax is a Leading Online Wealth Management platform in China. The Company’s business includes three major platforms: wealth management business, credit management business, and institutional service business.
    For more details,
  • VCredit
    Founded in 2006, VCredit is one of the pioneers of unsecured consumer credit in China. The Company has since grown into a leading on-line consumer credit company providing its users with a fully online credit services platform. VCredit was listed on the Hong Kong Stock Exchange on June 21, 2018 (HKSE stock code: 2003).
    For more details,
  • Tuhu.cn
    The Company was founded in Shanghai in 2011 and is now the largest auto care e-commerce platform in China, providing customers with a comprehensive B2C auto-care services platform.
    For more details,
  • Mafengwo
    Founded in 2011, the Company is a leading online travel platform in China, providing users with trip planning advise and online booking service during their travel by a variety of user-generated contents and online merchants.
    For more details,
    please refer to http://www.mafengwo.cn/
投资案例
  • Animoca Brands
    Animoca Brands是基于NFT(非同质化代币) 的区块链游戏和数字产权新兴市场的领导者。该公司拥有非常成功的区块链游戏和元游戏组合,包括Sandbox,F1 Delta Time和RevvRacing等。此外,Animoca在相关区块链游戏和NFT项目中拥有百余项战略投资。
    更多详情,请参阅  https://www.animocabrands.com /
  • 圣诺医药
    通过发现和开发未满足医疗需求的人类疾病的治疗方法,圣诺医药是第一家也是唯一一家在美国和中国拥有强大影响力的临床状态RNA治疗的生物制药公司。该公司临床开发管线的重点方向是肿瘤和纤维化适应症类别。圣诺医药于2021年12月30日在香港联合交易所上市(香港证券交易所股票代码:2257)。
    更多详情,请参阅  https://sirnaomics.com
  • 嘉和生物药业
    嘉和生物药业有限公司(“嘉和”)是一家领先的生物制药公司,专注于肿瘤及自身免疫药物的研发和商业化。公司总部位于上海,由高瓴资本和杭州泰格医药科技股份有限公司主导,于2018年6月从云南沃森生物技术股份有限公司分拆成立。嘉和已成功研发出靶向通路且极具潜力的候选药物,涵盖全球前三大肿瘤靶标及十款畅销药物中的五款。嘉和已建立由15款靶向候选药物组成的产品管线,该等药物在中国具有巨大的商业潜力,涵盖已知及新型生物学通路。嘉和已在中国设立了三大办事处(上海、云南玉溪和北京),并在美国旧金山创立了实验室。公司目前拥有约400名员工。
    更多详情,请参阅  https://www.genorbio.com/cn/about-genor/
  • 平安好医生
    平安好医生由平安集团于2014年8月成立。平安好医生是中国互联网医疗市场的先行者,运营着中国最大的互联网医疗平台(根据平均月活和每日平均在线问诊量衡量)。 通过2015年4月推出的移动平台,平安好医生提供在线医疗和健康服务,例如家庭医生服务、用户健康服务、健康商城以及与用户的健康管理互动。 平安好医生已于2018年5月4日在香港证券交易所上市(股票代码:1833)。
    更多详情,请参阅  https://www.jk.cn/aboutUs
  • 陆金所
    平安集团于2011年9月成立陆金所,陆金所是一家中国领先的在线财富管理平台。公司主营业务包括:财富管理业务、信用管理业务、机构服务业务。
    更多详情,请参阅  https://www.lu.com/about/aboutus.html
  • 维信金科
    维信金科成立于2006年,是中国消费信贷的探索者。该公司已经成长为一家领先的在线消费金融公司,为其用户提供全面的在线信贷服务。 维信金科已于2018年6月21日在香港证券交易所上市(股票代码:2003)。
    更多详情,请参阅  https://www.vcredit.com/about-us/about-us/
  • 途虎养车
    途虎养车于2011年成立于上海,目前是中国最大的汽车养护电商平台,为用户提供全面的B2C汽车养护服务。
  • 马蜂窝
    马蜂窝成立于2011年,是中国领先的在线旅游社区之一。马蜂窝通过用户原创内容和其线上电商服务,为用户提供旅游规划建议和在线预订。
    更多详情,请参阅  http://www.mafengwo.cn/
SERVICES

We provides investment advisory and asset management services to instititutions and high net worth individuals and families. Our focus includes private equity funds, direct investments and hedge funds.

We are an advisor to NM Strategic Management, LLC, the investment manager of NM Strategic Focus Fund. NM Strategic Focus Fund is a private equity fund with a focus on making direct investments in companies in the areas of technology, fintech, health care and consumer services in the People’s Republic of China.

服务

我们为机构及高净值客户提供投资咨询和资产管理服务。我们致力于私募股权基金、直接投资和对冲基金领域的投资服务。

我们是NM Strategic Management, LLC的咨询顾问,而NM Strategic Management, LLC为NM Strategic Focus Fund的基金管理人。NM Strategic Focus Fund是一家私募股权基金,专注于投资中国境内的高科技、金融科技、医疗健康以及消费服务行业的直接投资。

MANAGEMENT TEAM
  • Mr. Ng joined GRE as the CEO and NewMargin as a Managing Partner in June 2013. Mr. Ng has over twenty-one years of Global Investment Banking experience spanning across Hong Kong, China, the Asia Pacific region, New York, Sydney and London.

    Before joining GRE and NewMargin, Mr. Ng worked at J.P. Morgan for 7 years and he was Chairman as well as head of J.P. Morgan’s Asia Pacific Equity Capital and Derivatives Markets, focus on raising capital for both public and private companies via Initial Public Offerings, Equity & Equity-linked Offerings as well as pre-IPO private Placements.Prior to joining J.P. Morgan in 2006, Mr. Ng was at Merrill Lynch for over ten years and was a Managing Director and Head of Great China Equity Capital Markets. Prior to that, he has also worked at UBS’ Advisory & Financing Division in London and Goldman Sachs, Equity Capital Markets Division in London and Hong Kong.

    Throughout his Career, he has worked on some 500 equity and equity-linked transactions in Asian Pacific, including some 250 transactions for Greater China Companies, raising some $180 billion for them. In addition, he has worked on over 90 initial public offerings and pre-IPO placements, raising over $100 billion for Greater China companies listed on most of the major stock exchanges globally (Hong Kong, New York, London, Singapore, NASDAQ, etc.).

    Besides his Equity Capital Markets roles at J.P. Morgan, he has served as a director of the boards of both J.P Morgan Securities (Asia Pacific) Limited and J.P. Morgan Broking (Hong Kong) Limited. He was also a member of the J.P. Morgan Asia Pacific Equity Commitment Committee which is responsible for vetting and approving all of J.P. Morgan’s equity & equity linked transactions across the Asia Pacific Region. In addition, he also previously served as a Hong Kong SFC Responsible Officer as well as a Hong Kong Monetary Authority Executive Officer.

  • Mr. Kevin Yip is the managing director and responsible officer of GRE Investment Advisors Limited, a Hong Kong Securities and Futures Commission licensed advisor to NM Strategic Management, LLC. He is also a managing director of General Oriental Investments (HK) Limited, a wholly owned subsidiary of General Oriental Investments S.A., the investment manager of the Cavenham Group of Funds. Mr. Kevin Yip is also a non-executive director and a member of the audit committee of VCREDIT Holdings Limited which is listed on the Main Board of the Stock Exchange.

    Mr. Kevin Yip has extensive experience in private equity, alternative and portfolio investment. He was previously managing director and responsible officer of Bosera Asset Management (International) Co., Limited in Hong Kong. Prior to that he was a founding and senior partner of General Enterprise Management Services (HK) Limited, a private equity management company. He was previously a vice president of JP Morgan International Capital Corporation.

    Mr. Kevin Yip is currently a member of the Investment Advisory Committee of EQT Partners, a leading private equity group in Europe, which works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

    Mr. Kevin Yip holds an A.B. Degree in Economics (magna cum laude) from Harvard University. He sits as a non-scientific member of the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster and is a member of the Routine and Expedited Panel of the Hospital Authority Central Institutional Review Board. He was chairman emeritus of the Hong Kong Venture Capital and Private Equity Association. He had also served on the Financial Services Advisory Committee of the Trade Development Council of the Hong Kong Special Administrative Region of the People’s Republic of China.

  • Mr. Woo is the Managing Director and Responsible Officer of GRE. Mr. Woo has 30 years of experience in the finance industry, specializing in the corporate finance and asset management.

    He was with JP Morgan for 15 years, holding various investment banking and asset management positions in Hong Kong and New York. He also held investment banking position with DBS Bank, as Managing Director and Head of DBS Asian Capital Ltd.

    Mr. Woo also had experience as a regulator for 3 years in Hong Kong, serving as an executive director of the Mandatory Provident Fund Schemes Authority. Mr. Woo is a Chartered Financial Analyst, and obtained a B.Sc degree from University of Calgary and an MBA from the University of Hong Kong.

  • Mr. Cary Zhou is a partner of GRE and previously served as a Senior Partner with New Margin Ventures since 2007.

    For over the years, Mr. Zhou has worked throughout China beginning with AT&T Bell Labs as senior engineer for telecommunications, followed by a move to Lucent Technology (China) resulting in his role as a Vice President of Sales & Marketing. At Lucent, he was the Chief Representative of Lucent Technology for southern China, where he was responsible for the oversight of all of Lucent's activities in the region, including with respect to government relationships. Mr. Zhou also set up the Lucent Joint Venture in China and was the General Manager for Lucent Technologies of Shanghai Joint Venture.

    Mr. Zhou received his B.S. and M.S. degrees in Electrical Engineering from the Polytechnic University of New York. He has industry background, extensive government relationships in China, experience with publicly traded companies and demonstrated business expertise.

  • Mr. Zhuo is a venture partner of GRE and a founding partner of V-star Capital. Before V-star, Mr. Zhuo served as a partner in New Margin Ventures from 2009 to 2017. Prior to New Margin, he worked for J.P Morgan Securities (Asia Pacific) Limited for 5 years, participating in a series of global IPOs and M&A for Chinese companies.

    Mr. Zhuo received his bachelor’s degree in International Securities, Investment and Banking (ISIB) from ICMA Centre, the University of Reading.

  • Mr. Xu is the Vice President of GRE and NM Strategic Focus Fund L.P. He joined NM Strategic Partners, which is an independent USD GP sponsored by the NewMargin Group, since 2015. Before NewMargin, He was working as an auditor in Deloitte from 2010, mainly serving companies listed in US or compliance with US GAAP.

    Mr. Xu received his bachelor’s degree of Economics from the Shanghai University of Finance and Economics (2006-2010), as well as a diploma of Finance and Economics from the University of Southampton (2008-2009). Mr. Xu mainly focuses on TMT related sectors and AI at growth stage in China. Mr. Xu has earned the Chartered Financial Analyst (CFA) designation.

  • Mrs. Gong serves as an associate of GRE. Prior to joining GRE, Mrs. Gong has 6-year working experience in the private equity sector, focusing on post-investment management and fund operation.

    Mrs. Gong was previously an auditor at PWC, focusing on the private equity and mutual fund sector. During that period, she provided assurance service, including statutory audit and internal control services, to over 30 funds across China.

    Mrs. Gong received her bachelor’s degree of Economics from Shanghai University of Finance and Economics in 2011.

  • Mrs.Zhao is an associate of GRE.

    Before GRE, she was an analyst at East Bell Venture Capital, one of the leading venture capitals in China, focusing on B2B related sectors. Before East Bell, she works for the Meritco Group, one of the leading management consulting companies in China founded by McKinsey senior alumnus, specializing in providing commercial due diligence for top venture capitals and private equities globally, as well as corporation strategy management for top internet enterprises in China.

    Mrs.Zhao received her bachelor’s degree of Management from Shanghai University of Finance and Economics in 2013, and a master’s degree of International Business from Monash University in Australia in 2015 with a distinction performance.

  • Mr. Ho joined GRE as our Chief Financial and Compliance Officer in June 2022.  Mr. Ho has over 25 years of experience in audit, finance, compliance, and fund investment and administration experience. 

    Mr. Ho was the Controller/CFO and Executive Director for more than 10 years of several investment funds including hedge fund, real estate fund and private equity fund. During this period, Mr. Ho also served as the Financial Controller and Company Secretary of several Hong Kong listed companies to handle statutory financial reporting, compliance with the SFC and HK listing rules.

    Prior to that, he worked for Resources Global Professionals in Hong Kong, the PRC, and Tokyo, Japan as a Consultant, assisting clients on accounting, merger and acquisitions and financial due diligence in Hong Kong, the PRC and Tokyo, Japan.

    Prior to Resources Global Professionals, Mr. Ho was the Finance Manager of Simplex Capital Asia Limited, which involved direct investments in Hong Kong and the PRC.  Mr. Ho’s main responsibilities included management reporting, company secretarial work, compliance with regulating authorities and analyzing and monitoring the financial position of the fund's direct investments.  Prior to Simplex Capital Asia, he was stationed in Shenzhen & Guangzhou as an Audit Senior with Arthur Andersen & Co.  Mr. Ho began his career as an auditor for Ernst & Young in Hong Kong.

    Mr. Ho received a B.A. (Hons) Degree in Accountancy from Hong Kong Polytechnic University.   He is a Fellow Member of The Association of Chartered Certified Accountants (FCCA) and an Associate Member of the Hong Kong Institute of Certified Public Accountants (CPA).

管理团队
  • 吴绳祖先生于2013年6月加入GRE,担任首席执行官,并在上海永宣创业投资管理有限公司(NewMargin Ventures)担任管理合伙人。吴先生拥有超过21年的全球投资银行经验,遍及香港、中国内地、亚太地区、纽约、悉尼和伦敦。

    在加入GRE和上海永宣之前,吴先生在摩根大通工作了7年,是摩根大通亚太股权和衍生品市场部门(Equity Capital and Derivatives Markets)的主席以及部门主管,专注于通过首次公开发行(IPO)等方式为上市和私营企业融资。 在2006年加入摩根大通之前,吴先生在美林证券(现美银美林)有十余年工作经验,并曾任美林大中华区股权资本市场(Great China Equity Capital Markets)董事总经理和主管。此前,他还在瑞银伦敦的咨询与融资部门(Advisory & Financing Division),以及高盛伦敦和香港的股权资本市场部门(Equity Capital Markets Division)工作。

    吴绳祖先生参与了亚太地区约500笔股权和股权相关交易,包括了为大中华区企业服务的约250笔交易,为这些公司筹集了约1,800亿美元的资金。此外,他还参与了90多宗IPO和Pre-IPO的交易,为在全球大多数主要证券交易所(香港、纽约、伦敦、新加坡、纳斯达克等)上市的大中华区公司筹集了逾1000亿美元资金。

    除了在摩根大通担任股权资本市场的职务外,他还曾同时担任摩根证券(J.P Morgan Securities)亚太区及摩根大通期货(J.P. Morgan Broking)香港董事会的董事。另外,他也是摩根大通亚太区股权承诺委员会(Equity Commitment Committee)的成员,该委员会负责审批摩根大通在亚太区的所有股权和股权相关交易。此外,他亦曾担任香港证监会的负责官员及香港金融管理局执行官。

  • 叶家祺先生现任 GRE Investment Advisors Limited的董事总经理及负责人员。他同时也是 General Oriental Investments (HK) Limited(General Oriental Investments S.A.的全资附属公司)的董事总经理,General Oriental Investments S.A.是Cavenham Group of Funds的投资经理。叶家祺先生也是维信金科控股有限公司的非执行董事及公司审核委员会成员(一家于联交所主板上市的公司)。

    叶家祺先生在私募投资、另类及组合投资方面拥有丰富的经验。他曾任博时基金(国际)有限公司香港地区的董事总经理及负责人员。在此之前,他是湛思投资管理(香港)有限公司(一家私募投资管理公司)的创办人及高级合伙人。他曾任JP Morgan International Capital Corporation的副总裁。

    叶家祺先生现为EQT Partners(一家欧洲主要私募投资集团)的策略投资委员会的成员,EQT Partners致力与所投公司达成持续增长、卓越营运及维持市场领导地位。

    叶先生现为殷拓集团(EQT Partners)投资咨询委员会的成员。殷拓集团是一家欧洲领先的私募股权投资集团,致力于通过与其被投企业的联动,提高其被投企业可持续增长能力、运营效率及市场地位。

    叶家祺先生持有美国哈佛大学经济系文学士学位,并以优等成绩毕业。他是香港大学及医管局港岛西医院联网研究伦理委员会的非医疗卫生界成员及医管局中央研究伦理委员会Routine and Expedited Panel成员。他曾是香港创业及私募投资协会的荣誉主席。他也曾服务于中华人民共和国香港特别行政区贸易发展局金融服务咨询委员会。

  • 吴积民先生是GRE的常务董事兼负责人。吴先生在金融行业有30年的从业经验,专注于企业理财和资产管理。

    吴先生在摩根大通工作了15年,曾在香港和纽约担任众多投资银行和资产管理的职位。他还曾在星展银行担任其亚洲资本有限公司董事总经理及主管。

    吴先生亦曾在香港监管机构从业3年,担任强制性公积金计划管理局(Mandatory Provident Fund Schemes Authority)的执行董事。 吴先生是一名特许金融分析师,并获得加拿大卡尔加里大学理学学士学位及香港大学工商管理硕士学位。

  • 周永凯先生是GRE的合伙人。

    自2007年以来,他也曾担任上海永宣创业投资管理有限公司(NewMargin Ventures)的高级合伙人。多年来,周先生一直在中国各地工作。周先生的职业生涯从在美国电话电报公司贝尔实验室(AT&T Bell Labs)担任电信高级工程师开始,后来进入朗讯科技(中国)担任销售和营销副总裁。

    他是朗讯技术中国华南地区的首席代表,负责监督朗讯在该地区的所有活动,其中包括与政府关系的处理。周先生还在中国设立合资企业,并担任朗讯上海合资企业的总经理。

    周先生持有纽约理工大学电气工程学学士和硕士学位。他在中国有广泛的行业背景和政府关系,以及与各类上市公司的合作经验。

  • 卓星煜先生是GRE的风险合伙人及源星资本的创始合伙人。

    在创立源星资本之前,卓先生曾于2009至2017年担任上海永宣创业投资管理有限公司(NewMargin Ventures)的合伙人。在上海永宣之前,他在摩根证券(亚太)有限公司工作5年,参与过一系列中国企业在全球IPO和并购活动。

    卓先生于英国雷丁大学国际金融市场管理中心获得国际证券、投资及银行学学士学位(ISIB)。

  • 许晓辰先生是GRE的副总裁。自2015年起,他加入了上海永宣创业投资管理有限公司(NewMargin Ventures)的独立的美元基金团队。在上海永宣之前,他自2010年起在德勤担任审计师,主要服务于在美国上市或符合美国公认会计准则的中国企业。

    许先生获得上海财经大学经济学学士学位(2006-2010),及英国南安普顿大学金融经济学学位证书(2008-2009)。许先生主要专注于中国互联网相关行业以及人工智能方向的投资及研究。许先生是一名注册金融分析师(CFA)。

  • 龚晓蓉女士是GRE的投资经理。在加入GRE之前,龚女士在私募股权领域有6年的工作经验,专注于投后管理和基金运营。

    龚女士曾在普华永道担任审计师,专注于私募股权和共同基金领域。在此期间,她为全国30多家私募和公募基金提供保证服务,包括法定审计和内部控制。

    龚女士于2011年获得上海财经大学经济学学士学位。

  • 赵越女士是GRE的投资经理。

    在加入GRE之前,她是钟鼎创投的分析师,专注于B2B相关领域。在此之前,她服务于久谦咨询,专门为全球顶级风险投资和私募股权机构提供商业尽职调查,以及为中国顶级互联网企业提供企业战略管理。

    赵女士于2013年获得上海财经大学管理学学士学位,2015年以优异成绩获得澳大利亚莫纳什大学国际商务硕士学位。

  • 何知源先生于2022年6月加入GRE担任首席财务官和合规总监。何先生在审计、财务、合规、基金投资和行政方面拥有超过25年的工作经验。

    何先生曾在数家投资基金累计超过10年担任财务总监/ 首席财务官和执行董事的角色,包括对冲基金、房地产基金和私募股权基金。在此期间,何先生还曾担任多家香港上市公司的财务总监和公司秘书,处理法定财务报告,合规遵守香港证监会和上市规则。

    在此之前,他曾在香港、中国大陆和日本东京的Resources Global Professionals担任顾问,协助客户在香港、中国大陆和日本东京当地的会计、并购和财务尽职调查。

    在加入Resources Global Professionals之前,何先生是先策投资亚洲有限公司的财务经理,该公司涉及在香港和中国大陆的直接投资。何先生的主要职责包括管理报告、公司秘书工作、遵守监管部门的规定以及分析和监督该基金直接投资的财务状况。在加入先策投资亚洲有限公司之前,他在深圳及广州安达信公司担任高级审计师。何先生职业生涯的最初是一名香港安永会计师事务所的审计师。

    何先生持有香港理工大学会计(荣誉)学士学位。他是英国特许公认会计师公会(FCCA)的资深会员及香港会计师公会(CPA)的会员。

CONTACT
ADDRESS
Principal Place of Business
Suite 3406 Jardine House, 1 Connaught Place, Central, Hong Kong
Telephone & Fax
Tel: +852 2360 2798
Fax: +852 2360 2799
Email
Kevin Yip: kyip@gre-inv.com
Kester Ng: kng@gre-inv.com
© GRE INVESTMENT ADVISORS LIMITED. All rights reserved.
联系我们
公司地址
香港中环康乐广场1号怡和大厦3406室
电话和传真
电话: +852 2360 2798
传真: +852 2360 2799
电子邮件
叶家祺: kyip@gre-inv.com
吴绳祖: kng@gre-inv.com
© GRE INVESTMENT ADVISORS LIMITED. All rights reserved.
EN / 中文